Raju Prasad's Insider Trades & SAST Disclosures
Raju Prasad's most recent trade in CRISPR Therapeutics AG was a trade of 6,250 Common Shares done . Disclosure was reported to the exchange on March 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Raju Prasad.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 18,964 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 18,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 20 Mar 2025 | 2,197 | 16,767 (0%) | 0% | 41.2 | 90,582 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 36,666 | 36,666 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 27,500 | 27,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 10,000 | 20,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 10,000 | 16,476 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.80 per share. | 14 Mar 2025 | 3,762 | 12,714 (0%) | 0% | 41.8 | 157,252 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 18,333 | 18,333 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 36,168 | 36,168 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 10,000 | 30,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 10,000 | 10,000 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 72.69 per share. | 14 Mar 2024 | 3,524 | 6,476 (0%) | 0% | 72.7 | 256,160 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 40,000 | 40,000 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges